EOLS
Evolus Inc

3,841
Mkt Cap
$473.18M
Volume
2.33M
52W High
$17.12
52W Low
$5.71
PE Ratio
-8.00
EOLS Fundamentals
Price
$7.37
Prev Close
$7.30
Open
$7.27
50D MA
$6.64
Beta
0.98
Avg. Volume
993,134.65
EPS (Annual)
-$0.813
P/B
-16.44
Rev/Employee
$802,030.12
Loading...
Loading...
News
all
press releases
Evolus (NASDAQ:EOLS) Posts Earnings Results, Misses Expectations By $0.10 EPS
Evolus (NASDAQ:EOLS - Get Free Report) released its earnings results on Wednesday. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates
Evolus (EOLS) delivered earnings and revenue surprises of +26.32% and +1.70%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8d ago
News Placeholder
Earnings Preview: Prestige Consumer Healthcare (PBH) Q2 Earnings Expected to Decline
Prestige Consumer Healthcare (PBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·14d ago
News Placeholder
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·15d ago
News Placeholder
Evolus to Participate in 2025 Stifel Healthcare Conference
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a...
Business Wire·17d ago
News Placeholder
Evolus to Report Third Quarter Financial Results on November 5, 2025
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2025 financial...
Business Wire·23d ago
News Placeholder
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in October of non-qualified stock options to...
Business Wire·1mo ago
News Placeholder
Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates
Evolus (EOLS) delivered earnings and revenue surprises of -166.67% and -16.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·4mo ago
News Placeholder
Earnings Preview: Evolus, Inc. (EOLS) Q2 Earnings Expected to Decline
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·4mo ago

Latest EOLS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.